Verve Therapeutics
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Beam, Verve stockpile cash as investors bank on gene editing progress
Post navigation
Previous Post
Previous
Why Verve chose base editing over standard CRISPR for its lead CV candidate
Next Post
Next
CRISPR 2.0: Base Editing in the Groove
Home
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Contact Us